Andre D. Harvin, PharmD, MS, MBA

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and collaboration drive the growing integration of SubQ formulations as a convenient and adaptable option in cancer care.

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the broader adoption of subcutaneous (SubQ) oncology therapies, underscoring the need for coordinated stakeholder collaboration and education to drive integration.

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement models, highlighting the need for collaborative education and flexible care strategies to ensure patient-centered, financially viable implementation.

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer coordination, billing oversight, and nurse retraining to ensure both financial sustainability and safe, efficient patient care.

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical record (EMR) readiness, workflow adaptation, and patient-centered communication to ensure safe, efficient, and individualized care.

Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ensure that treatment choices align with clinical appropriateness, patient preferences, and operational readiness.

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot strategies—combined with strong leadership and patient education—to enhance efficiency, staff engagement, and the overall care experience.

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments to ensure financial viability, clinical effectiveness, and enhanced patient satisfaction.

Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ongoing evaluation to ensure improved care quality and operational efficiency.

Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with pharmacy and therapeutics committees balancing patient benefit, operational feasibility, and financial risk to guide adoption.

Panelists discuss how subcutaneous (SubQ) oncology treatments are reshaping clinic operations by improving infusion chair utilization, enabling flexible scheduling, streamlining pharmacy workflows, and prompting new care delivery models that enhance both efficiency and patient experience.

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ultimately supporting a more scalable and sustainable care model.

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health care efficiency, and clinical workflows in light of recent FDA approvals and evolving pharmaceutical strategies.

Panelists discuss how the successful management of iron deficiency anemia requires a comprehensive approach combining early detection, appropriate choice of iron formulation, careful monitoring of treatment response, and addressing barriers to care while emphasizing the importance of patient education and health care system support in achieving optimal outcomes.

Panelists discuss how expanding patient education initiatives through digital health tools, community outreach, and health care provider collaboration could improve early recognition of IDA symptoms and treatment adherence, while emerging technologies like novel iron formulations and personalized medicine approaches may further advance treatment options in the future.

Panelists discuss how increasing insurance step edit requirements for high-dose IV iron formulations have created barriers to optimal patient care, requiring providers to implement strategic prior authorization processes and develop documentation protocols to demonstrate medical necessity while advocating for appropriate patient access to these medications.

Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and administering IV iron treatments, leading clinicians to favor products that can achieve iron repletion in fewer sessions.

Panelists discuss how nonadherence to IV iron therapy can lead to persistent anemia, worsening symptoms, increased health care utilization and costs, and diminished quality of life, with patients experiencing continued fatigue, reduced work productivity, and increased risk of complications from their underlying conditions.

Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic complications such as osteomalacia and metabolic disturbances, potentially impacting patients’ mobility, energy levels, and overall quality of life if not properly monitored and managed.

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility requirements for administration, while emphasizing that modern formulations have significantly improved safety profiles compared with older products.

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and iron sucrose, offer improved safety profiles and more efficient iron delivery compared with older compounds, thanks to their more stable carbohydrate shells and controlled iron release mechanisms.

Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including gastrointestinal adverse effects and poor absorption, leading many patients to experience iron intolerance or inadequate response, which often necessitates switching to intravenous iron administration for more reliable and rapid repletion of iron stores.

Panelists discuss how monitoring patients with iron deficiency anemia requires regular follow-up appointments to track laboratory values, assess symptom improvement (particularly fatigue), and evaluate treatment response while considering the impact of comorbid conditions, with adjustments to therapy made based on both objective markers and patient-reported outcomes.

Panelists discuss how diagnosing iron deficiency anemia requires comprehensive laboratory testing of iron parameters alongside clinical assessment, emphasizing early detection to prevent complications in patients with common comorbidities like chronic kidney disease, heart failure, and inflammatory bowel disease, where coordinated treatment approaches must balance managing both IDA and the underlying condition.

Panelists discuss how iron deficiency anemia manifests through debilitating symptoms, including severe fatigue, weakness, shortness of breath, headaches, and difficulty concentrating, which can profoundly impact patients’ daily functioning, work performance, and overall quality of life.

Panelists discuss how iron deficiency anemia significantly impacts patients’ quality of life through symptoms like chronic fatigue, shortness of breath, and cognitive dysfunction, while also creating substantial psychosocial burdens including depression, reduced work productivity, and social isolation, particularly affecting vulnerable populations who may face barriers to diagnosis and treatment.

Panelists discuss how chronic kidney disease leads to iron deficiency anemia through a complex interplay of impaired iron absorption, increased hepcidin production driven by inflammatory cytokines, and reduced erythropoietin synthesis, resulting in both functional and absolute iron deficiency alongside diminished red blood cell production.